687
im a white ass nigger
- Joined
- Jun 26, 2026
- Posts
- 110
- Reputation
- 61
Lets talk about proviron
Mesterolone (Proviron) is a well-known paradoxical androgenic/anabolic steroid because, despite possessing very high affinity for the androgen receptor and being structurally derived from DHT, it produces very little skeletal muscle hypertrophy compared to virtually every other anabolic steroid.
This is because skeletal muscle expresses substantial levels of aldo-keto reductase enzymes, specifically 3α-hydroxysteroid dehydrogenase AKR1C2. These rapidly convert DHT-derived androgens like Proviron into less active 3α-reduced metabolites before they exert prolonged genomic effects on the androgen receptor.
Mesterolone may bind the receptor strongly, but virtually all of the drug is metabolically inactivated within muscle tissue. To fix this, we need an AKR1C enzyme inhibitor.
Flufenamic acid and meclofenamic acid belong to the fenamate class of NSAIDs, and are known to interact with members of the AKR1C enzyme family, particularly AKR1C2. At the molecular level, fenamates bind within the enzyme’s pocket and create steric and energetic competition with the substrates. This reduces its efficacy by many levels, letting Proviron work in muscle tissue
How do we get our hands on these substances? Which ones do I take? Meclofenamate (the drug/encapsulated form) is biologically more plausible to work due to slightly more AKR1C2 relevance, whilst flufenamic acid is better for AKR1C (but still targets AKR1C2). Both of them are used clinically in some countries, though less common today due to safer and more effective treatment methods.
The theory becomes less attractive due to inhibition of cyclooxygenase pathways, leading to potential GI effects, water retention and mild cardiovascular risks.
Risks:
Due to cyclooxygenase pathway inhibition (arachidonic acid, prostaglandins):
• Gastritis
• Ulcers
• GI bleeding
• Less kidney perfusion
• Fluid retention
• High blood pressure
• Cardiovascular risk
The major one being less prostaglandins, lowering remodeling and hypertrophy signaling.
This is fixable. Misoprostol (prostaglandin analog), high testosterone, and omega-6 fatty acids fix the prostaglandin issue.
Overall
5/10 for safety, 8/10 for mechanism of action. This is not theoretical biology but mechanistically possible and can work when paired with the right substances. If managed properly, we could have substantial muscle growth with minimal suppression and high dimorphism.
Mesterolone (Proviron) is a well-known paradoxical androgenic/anabolic steroid because, despite possessing very high affinity for the androgen receptor and being structurally derived from DHT, it produces very little skeletal muscle hypertrophy compared to virtually every other anabolic steroid.
This is because skeletal muscle expresses substantial levels of aldo-keto reductase enzymes, specifically 3α-hydroxysteroid dehydrogenase AKR1C2. These rapidly convert DHT-derived androgens like Proviron into less active 3α-reduced metabolites before they exert prolonged genomic effects on the androgen receptor.
Mesterolone may bind the receptor strongly, but virtually all of the drug is metabolically inactivated within muscle tissue. To fix this, we need an AKR1C enzyme inhibitor.
Flufenamic acid and meclofenamic acid belong to the fenamate class of NSAIDs, and are known to interact with members of the AKR1C enzyme family, particularly AKR1C2. At the molecular level, fenamates bind within the enzyme’s pocket and create steric and energetic competition with the substrates. This reduces its efficacy by many levels, letting Proviron work in muscle tissue
How do we get our hands on these substances? Which ones do I take? Meclofenamate (the drug/encapsulated form) is biologically more plausible to work due to slightly more AKR1C2 relevance, whilst flufenamic acid is better for AKR1C (but still targets AKR1C2). Both of them are used clinically in some countries, though less common today due to safer and more effective treatment methods.
The theory becomes less attractive due to inhibition of cyclooxygenase pathways, leading to potential GI effects, water retention and mild cardiovascular risks.
Risks:
Due to cyclooxygenase pathway inhibition (arachidonic acid, prostaglandins):
• Gastritis
• Ulcers
• GI bleeding
• Less kidney perfusion
• Fluid retention
• High blood pressure
• Cardiovascular risk
The major one being less prostaglandins, lowering remodeling and hypertrophy signaling.
This is fixable. Misoprostol (prostaglandin analog), high testosterone, and omega-6 fatty acids fix the prostaglandin issue.
Overall
5/10 for safety, 8/10 for mechanism of action. This is not theoretical biology but mechanistically possible and can work when paired with the right substances. If managed properly, we could have substantial muscle growth with minimal suppression and high dimorphism.
